1. Home
  2. NGNE vs XNET Comparison

NGNE vs XNET Comparison

Compare NGNE & XNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$22.28

Market Cap

327.8M

Sector

Health Care

ML Signal

N/A

Logo Xunlei Limited

XNET

Xunlei Limited

N/A

Current Price

$6.56

Market Cap

356.5M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
NGNE
XNET
Founded
2003
2003
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
356.5M
IPO Year
2014
2011

Fundamental Metrics

Financial Performance
Metric
NGNE
XNET
Price
$22.28
$6.56
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$60.13
N/A
AVG Volume (30 Days)
157.3K
162.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$925,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$0.29
Revenue Growth
N/A
N/A
52 Week Low
$6.88
$2.83
52 Week High
$37.27
$11.03

Technical Indicators

Market Signals
Indicator
NGNE
XNET
Relative Strength Index (RSI) 56.11 61.81
Support Level $19.44 $6.50
Resistance Level $25.79 $6.60
Average True Range (ATR) 2.28 0.30
MACD 0.24 0.11
Stochastic Oscillator 51.91 76.97

Price Performance

Historical Comparison
NGNE
XNET

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

Share on Social Networks: